Article processing charges (APCs) support peer review coordination, editorial management, production, DOI registration, and long term digital archiving. APCs are applied after acceptance and do not influence editorial decisions.

JTC is committed to transparency and affordability for thyroid cancer research communities.

• Editorial assessment and peer review management
• Copyediting, layout, and publication production
• DOI registration and metadata validation
• Long term archiving and platform maintenance
• Open access hosting and global dissemination

Authors from World Bank classified low income and lower middle income countries may be eligible for partial APC waivers. Requests are evaluated on a case by case basis and must be submitted before acceptance.

Membership options offer discounted APCs for eligible authors and institutions. Contact the editorial office for guidance.

Many endocrine oncology teams publish under grant or institutional mandates. Share funder requirements early so the editorial office can align invoicing and reporting needs.

• Provide grant identifiers and funding statements
• Confirm open access mandates or repository requirements
• Share billing contacts for institutional or funder payments
• Document any reporting deadlines tied to publication
• If your institution requires invoice language or grant identifiers, provide them before acceptance to avoid delays.
• APC receipts include journal name, manuscript title, and DOI reference for institutional reporting.
• Payment can be made by institutions, funders, or authors. Coordinate billing details early to streamline processing.
• Requests for partial waivers should be submitted before acceptance with supporting documentation.
• APCs support long term digital preservation and open access distribution of thyroid cancer research.
• If a funding agency requires open access confirmation, the editorial office can provide verification after publication.
• Invoices can be issued to a central grants office when funding sources require consolidated billing.
• APC questions are handled by the editorial office; contact them early to align budgets with publication timelines.
• Provide billing contacts and purchase order details early to avoid administrative delays during production.
• Institutions covering APCs should confirm currency conversion requirements and tax exemptions if applicable.
• Waiver requests should include a brief justification and confirmation of eligibility criteria.
• If funding is pending, notify the editorial office so invoice timelines can be coordinated.
• Payment confirmations are required before copyediting and proof preparation begin.
• For multicenter studies, designate a single billing contact responsible for APC coordination.
• Report thyroid cancer subtype (papillary, follicular, medullary, anaplastic) and histologic variant.
• Include AJCC staging and ATA risk stratification details.
• Describe ultrasound features using TI-RADS or equivalent scoring.
• Report cytology classification using the Bethesda system.
• Provide tumor size, multifocality, and extrathyroidal extension data.
• Describe lymph node assessment methods and dissection extent.
• Report surgical approach and margin status (R0/R1/R2).
• Include postoperative thyroglobulin levels and antibody status.
• Specify radioactive iodine dose, preparation method, and response criteria.
• Define recurrence, persistence, and follow up intervals clearly.
• Describe imaging modalities used for surveillance and response assessment.
• Report complication rates such as hypocalcemia or recurrent laryngeal nerve injury.
• Provide survival outcomes and event definitions (DFS, OS, PFS).
• Include molecular profiling methods and mutation panels used.
• Report BRAF, RAS, RET, TERT, and other driver alterations when tested.
• Clarify indications for targeted therapies and response metrics.
• Describe criteria for RAI refractory disease.
• Include endocrine outcomes such as TSH suppression targets and dosing.
• Report quality of life or patient reported outcomes when available.
• Document consent procedures and ethics approvals for clinical studies.
• Describe inclusion/exclusion criteria and referral pathways.
• Provide details on family history or MEN2 screening when relevant.
• Clarify pathology review standards and interobserver agreement.
• Include reporting of vascular invasion or capsular invasion.
• Provide data on tumor microenvironment markers or immune profiling.
• Report use of RECIST or other response criteria for systemic therapy.
• Include trial registration identifiers for prospective studies.
• Describe statistical power calculations or sample size justification.
• Report handling of missing data and sensitivity analyses.
• Provide data availability statements and repository access details.
• Clarify whether imaging or pathology data are shareable and how.
• Describe multidisciplinary team involvement in treatment planning.
• Report adherence to guideline recommendations or deviations.
• Provide stratified outcomes by risk group or stage.
• Document long term adverse events or endocrine complications.
• Include details on ablative versus adjuvant RAI strategies.
• Report use of PET/CT or advanced imaging and rationale.
• Describe histopathologic criteria for aggressive variants.
• Provide local or regional recurrence management details.
• Clarify timing between diagnosis, surgery, and adjuvant therapy.
• Report preoperative vocal cord assessment and laryngeal nerve monitoring details.
• Include postoperative calcium management protocols and outcomes.
• Describe tumor growth patterns and variant classification criteria.
• Report detailed lymph node mapping and nodal yield metrics.
• Include timing and criteria for completion thyroidectomy when applicable.
• Provide details on active surveillance protocols for low risk disease.
• Report use of minimally invasive or robotic surgical approaches.
• Clarify criteria for lobectomy versus total thyroidectomy.
• Include outcomes stratified by sex and age when relevant.
• Report use of molecular risk calculators or nomograms.
• Describe dose adjustments for thyroid hormone suppression therapy.

To avoid delays, payments should be completed within 48 hours of invoice receipt. Publication proceeds after payment confirmation.

JTC is committed to rigorous, transparent publishing in thyroid cancer research and care. We emphasize reproducible clinical methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in endocrine oncology, surgical outcomes, and translational thyroid research.